Efficacy of Atezolizumab Plus Bevacizumab-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2024 Oct 25

PMID 39451736

Authors

Etsuko Moriyama

Shigeo Shimose

Takashi Niizeki

Hideki Iwamoto

Masatoshi Tanaka

Tomotake Shirono

Yu Noda

Masahito Nakano

Ryoko Kuromatsu

Hironori Koga

Takumi Kawaguchi

Affiliations

Soon will be listed here.

Abstract

This retrospective study aimed to evaluate the impact of atezolizumab plus bevacizumab-transcatheter arterial chemoembolization (TACE) sequential therapy in unresectable hepatocellular carcinoma (HCC), especially in patients with intermediate-stage HCC. A total of 212 patients were enrolled and categorized into the Atez/Bev-TACE sequential therapy ( = 23) or Atez/Bev monotherapy group ( = 189) between 2020 and 2024. Of these, patients with intermediate-stage HCC were categorized into the Atez/Bev-TACE sequential ( = 18) or Atez/Bev monotherapy group ( = 91). The best objective response rate, disease control rate, and median progression-free survival (PFS) after TACE were 73.9%, 82.6%, and 6.1 months, respectively. The PFS after TACE was significantly higher in the Atez/Bev sequential therapy group than in the no-Atez/Bev-administration group after TACE (6.9 months vs. 5.0 months, = 0.025). The median overall survival (OS) was significantly higher in the Atez/Bev-TACE sequential therapy group than in the Atez/Bev monotherapy group for intermediate-stage HCC (34.9 months vs. 17.8 months; = 0.016). Independent factors associated with OS were low alpha-fetoprotein levels, modified albumin-bilirubin 1 or 2a levels, and Atez/Bev-TACE sequential therapy. Atez/Bev-TACE sequential therapy improved prognosis compared with Atez/Bev monotherapy in patients with intermediate-stage HCC. Moreover, Atez/Bev should be readministered after TACE.

References

Cheng A, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2021; 76(4):862-873. DOI: 10.1016/j.jhep.2021.11.030. View

Villanueva A . Hepatocellular Carcinoma. N Engl J Med. 2019; 380(15):1450-1462. DOI: 10.1056/NEJMra1713263. View

Kudo M, Finn R, Qin S, Han K, Ikeda K, Piscaglia F . Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391(10126):1163-1173. DOI: 10.1016/S0140-6736(18)30207-1. View

Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N . Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. Liver Cancer. 2017; 6(4):325-336. PMC: 5704689. DOI: 10.1159/000479984. View

Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A . BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2021; 76(3):681-693. PMC: 8866082. DOI: 10.1016/j.jhep.2021.11.018. View

Finn R, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382(20):1894-1905. DOI: 10.1056/NEJMoa1915745. View

Freites-Martinez A, Santana N, Arias-Santiago S, Viera A . Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed). 2020; 112(1):90-92. DOI: 10.1016/j.ad.2019.05.009. View

Shimose S, Iwamoto H, Tanaka M, Niizeki T, Shirono T, Noda Y . Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. Cancers (Basel). 2021; 13(1). PMC: 7796435. DOI: 10.3390/cancers13010160. View

Fu Z, Li X, Zhong J, Chen X, Cao K, Ding N . Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Hepatol Int. 2021; 15(3):663-675. PMC: 8286947. DOI: 10.1007/s12072-021-10184-9. View

10.

Liang Y, Gan L, Zeng D, Lin L, Xiong Z, Liao F . Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. Clin Transl Oncol. 2024; 26(10):2652-2664. DOI: 10.1007/s12094-024-03458-9. View

11.

Carmeliet P, Jain R . Angiogenesis in cancer and other diseases. Nature. 2000; 407(6801):249-57. DOI: 10.1038/35025220. View

12.

Bolondi L, Burroughs A, Dufour J, Galle P, Mazzaferro V, Piscaglia F . Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2013; 32(4):348-59. DOI: 10.1055/s-0032-1329906. View

13.

Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A . Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008; 103(4):914-21. DOI: 10.1111/j.1572-0241.2007.01712.x. View

14.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

15.

Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H . Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2019; 69(8):1492-1501. PMC: 7398460. DOI: 10.1136/gutjnl-2019-318934. View

16.

Shimose S, Iwamoto H, Niizeki T, Tanaka M, Shirono T, Moriyama E . Efficacy of Lenvatinib Combined with Transcatheter Intra-Arterial Therapies for Patients with Advanced-Stage of Hepatocellular Carcinoma: A Propensity Score Matching. Int J Mol Sci. 2023; 24(18). PMC: 10530984. DOI: 10.3390/ijms241813715. View

17.

Hiraoka A, Kumada T, Michitaka K, Kudo M . Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. Liver Cancer. 2019; 8(5):312-325. PMC: 6873026. DOI: 10.1159/000494844. View

18.

Kudo M . A Changing Role of Transarterial Chemoembolization in the Era of Immune Checkpoint Inhibitor plus Anti-VEGF/TKI plus Transarterial Chemoembolization: From Total Embolization to Partial Embolization (Immune Boost Transarterial Chemoembolization). Liver Cancer. 2024; 13(4):335-343. PMC: 11305789. DOI: 10.1159/000539301. View

19.

Shimose S, Kawaguchi T, Iwamoto H, Niizeki T, Shirono T, Tanaka M . Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma. Oncol Lett. 2020; 19(4):2667-2676. PMC: 7068224. DOI: 10.3892/ol.2020.11399. View

20.

Iwamoto H, Shimose S, Niizeki T, Koga H, Torimura T . Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma. Clin Mol Hepatol. 2022; 28(3):575-579. PMC: 9293609. DOI: 10.3350/cmh.2022.0047. View